| Literature DB >> 22408578 |
Henk W R Schreuder, Thyrza O S Pattij, Ronald P Zweemer, Marchien W van Baal, René H M Verheijen.
Abstract
We assessed the effect of increasing experience of a single surgeon (learning curve) in the laparoscopic staging procedure for women with early ovarian cancer and compared the results with the literature. We retrospectively analysed a total of 25 women with apparent early-stage ovarian cancer who underwent a laparoscopic staging procedure by the same surgeon. Three time periods, based on date of surgery, were compared with respect to operating time, amount of lymph nodes harvested and surgical outcome. There was no significant difference in operation time, estimated blood loss and hospital stay between the three periods. There was, however, a significant increase in the median number of pelvic and para-aortal lymph nodes harvested (group1 = 6.5, group 2 = 8.0 and group 3 = 21.0; P < 0.005). For the total period, median operation time was 235 min and median estimated blood loss was 100 ml. The median length of hospital stay was 4.0 days. Two intraoperative and two postoperative complications occurred. The upstaging rate was 32%. The mean interval between initial surgery and laparoscopic staging was 51.2 days. Mean duration of follow-up was 43 months, range (1-116 months). Five (20%) patients had recurrences, and two (8%) patients died of the disease. In conclusion, there is a significant learning curve for the laparoscopic full staging procedure in ovarian cancer. In our study this is mainly reflected in the amount of lymph nodes harvested and not in the total operating time.Entities:
Year: 2011 PMID: 22408578 PMCID: PMC3285756 DOI: 10.1007/s10397-011-0692-6
Source DB: PubMed Journal: Gynecol Surg ISSN: 1613-2076
Patient characteristics
| Characteristics | Number |
|---|---|
| Patients | 25 |
| Mean age in years (range) | 49.7 (18–79) |
| BMI in kg/m2 (range) | 24.6 (17.4–36.5) |
| Histological types | |
| Adenocarcinoma | 16 |
| Clear cell | 4 |
| Borderline | 4 |
| Other | 1 |
| FIGO stage (before staging) | |
| IA | 12 |
| IB | 1 |
| IC | 9 |
| IIC | 2 |
| Unknown | 1 |
| Tumour grade | |
| Grade 1 | 10 |
| Grade 2 | 7 |
| Grade 3 | 5 |
| Unknown | 3 |
| Procedures at initial surgery | |
| Cystectomy | 3 |
| Adnectomy | 11 |
| Bilateral adnectomy | 5 |
| Hysterectomy + adnectomy | 1 |
| Hysterectomy + bilateral adnectomy | 4 |
| No initial surgery | 1 |
| Ovarian preservation procedure at secondary surgery | 4 |
| Mean age in years (range) | 32.3 (18–41) |
| Histologic type | |
| Borderline | 2 |
| Adenocarcinoma | 2 |
Surgical outcome
| Variable | |
|---|---|
| Operation time (min) | 235 (100–285) |
| Estimated blood loss (ml) | 100 (10–1,500) |
| Total LNNa | |
| Pelvic lymph nodes ( | 8.0 (3–31) |
| Para-aortic lymph nodes ( | 6.0 (2–12) |
| Overall ( | 8.0 (3–31) |
| Time between operations (days) | 54 ± 21 |
| Upstaging ( | 8 (32%) |
| Intraoperative complications ( | 2 (8%) |
| Postoperative complications ( | 2 (8%) |
| Postoperative hospital stay (days) | 4.0 (2–6) |
| Time to adjuvant chemotherapy (days) | 21 (±10.3) |
| Follow-up (months) | 43 (±31.5) |
Data are expressed as median (range), mean±standard deviation or number (in percentage)
aIn those patients where a pelvic and/or para-aortic lymphadenectomy was performed
Fig. 1Operating time and number of lymph nodes. Surgical procedures in chronological order: operating time (n = 25) and total number of lymph nodes [pelvic + para-aortal (n = 24) (scatter plot)]
Surgical outcome in time periods
| Group I (first period), | Group II (second period), | Group III (third period), |
| |
|---|---|---|---|---|
| Operative time (min) | 225.0 (100–260) | 245.0 (145–285) | 207.5 (181–270) | 0.095 |
| EBL (ml) | 50.0 (10–1,000) | 50.0 (20–200) | 100.0 (20–1,500) | 0.682 |
| Total number lymph nodesa | 6.5 (3–17) | 8.0 (3–21) | 21.0 (7–31) | 0.003 |
| Pelvica | 7.5 (1–12) | 3.0 (1–13) | 13.0 (4–19) | 0.023 |
| Para-aortica | 5.5 (2–7) | 4.0 (2–8) | 9.0 (3–12) | 0.017 |
| Hospital stay (days) | 3.0 (2–5) | 4.0 (3–6) | 3.5 (3–6) | 0.069 |
Data expressed as medians with range
aIn those patients where a pelvic and/or para-aortic lymphadenectomy was performed
Overview of literature for the laparoscopic staging procedure in early-stage ovarian cancer
| Laparoscopy | Number | Restaging/primary staging | OR time (min) | Delay (weeks) | Hospital stay (days) | PLN ( | PALN ( | EBL (ml) | Upstaging ( | Compl ( | Follow-up (months) | R ( | M ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Present series | 25 | 24/1 | 224 (100–285) | 7.3 (3.1–13.3) | 4.0 (2–6) | 13.8 (3–31) | 5.8 (2–12) | 193 (10–1,500) | 8 (32%) | 4 (16%) | 43 (1–116) | 5 | 2 |
| Nezhat et al. [ | 36 | 9/25 | 229 (59–386) | NA | 2.37 (1–5) | 14.84 (0–45) | 12.23 (0–53) | 195 (25–500) | 7 (19.4%) | 4 (11.1%) | 56 | 3 | 0 |
| Muzii et al. [ | 27 | 27/0 | 180 (130–300) | 6.8 (2–9) | 3 (2–7) | NA | NA | 200 (100–700) | 7 (26%) | 1 (3.7%) | 20 (7–38) | 1 | 0 |
| Jung et al. [ | 24 | 5/19 | 253.7 ± 65.7 | NA | 10.6 ± 4.0 | 22.5 ± 8.9 | 11.0 ± 5.8 | 567.0 ± 170.9 | 10 (41.7%) | 1 (4.2%) | 10 (2–39) | 1 | 1 |
| Park et al. [ | 19 | 7/12 | 221 ± 83 | 19 (7–34) | 8.9 ± 6.1 | 27.2 ± 9.7 | 6.6 ± 6.2 | 240 ± 228 | 4 (21.1%) | 2 (10.5%) | 17 (2–40) | 0 | 0 |
| Park et al. [ | 17 | 6 / 11 | 303.8 ± 84.9 | 35.8 | 9.4 ± 4.1 | 13.7 ± 5.6 | 8.9 ± 7.1 | 231.2 ± 117.9 | 1 (5.9%) | 2 (11.8%) | 19 (5–56) | 2 | 1 |
| Colomer et al. [ | 20 | 7/13 | 223 (180–320) | 4.7 (2–11.4) | 3.2 (1–7) | 18 (14–21) | 11.3 (7–23) | NA | 4 (20%) | 2 (10%) | 24.7 (1–61) | 1 | 0 |
| Ghezzi et al. [ | 15 | 5/10 | 377 ± 47 | 8 (5–14) | 3 (2–12) | 25.2 ± 9.3 | 6.5 ± 3.9 | 250 (50–1,000) | 4 (26.7%) | 2 (6.7%) | 16 (4–33) | 0 | 0 |
| Chi et al. [ | 20 | 13/7 | 321 ± 64 | NA | 3.1 ± 0.7 | L, 5.8 ± 2.9 | L, 2.9 ± 1.7 | 235 ± 138 | NA | 0 | NA | NA | NA |
| R, 6.5 ± 3.9 | R, 3.8 ± 1.8 | ||||||||||||
| Spirtos et al. [ | 58 | 58/0 | 187.9 ± 59.8 | NA | 3.35 ± 5.10 | L, 9.0 ± 6.0 | L, 5.3 ± 3.3 | 171.9 ± 128 | 8 (13.8%) | 11 (19%) | NA | NA | 0 |
| R, 9.6 ± 5.2 | R, 5.0 ± 3.4 | ||||||||||||
| Leblanc et al. [ | 53 | 42/11 | 238 (120–370) | 8.3 ± 4.8 | 3.1 (1–5) | 14 (4–27) | 20 (7–40) | NA | 8 (19%) | 4 (7.5%) | 54 (8–116) | 5 | 2 |
| Krivak et al. [ | 19 | 0/19 | 201 (90–350) | NA | 2 (1–8) | NA | NA | 271 (50–1,500) | 7 (36%) | 4 (16%) | 32 | NA | NA |
| Tozzi et al. [ | 24 | 11/13 | 176 (102–306) | 12 (4–21) | 7 (5–12) | 19.8 (14–29) | 19.6 (5–35) | NA | NA | 1 (4.1%) | 46 (2–72) | 2 | 0 |
| Leblanc et al. [ | 28 | 25/3 | 230 ± 67.5 | 8.3 (2–26) | 3.3 (1–6) | 13.7 (4–27) | 19.7 (5–40) | NA | 6 (21%) | 1 (3.7%) | 38 (2–89) | 1 | 1 |
| Amara et al. [ | 4 | 3/1 | 290 (190–335) | NA | 1.75 (1–2) | NA | NA | NA | NA | 0 | NA | NA | NA |
| Pomel et al. [ | 10 | 10/0 | 313 | NA | 4.75 (2–8) | 7.1 (3–13) | 8.8 (6–12) | NA | NA | 2 (20%) | NA | NA | NA |
| Childers et al. [ | 14 | 5/9 | 149 (120–240) | NA | 1.6 (0–3) | NA | NA | NA | 8 (57%) | 2 (14.3%) | NA | NA | NA |
| Querleu and Leblanc [ | 9 | 9/0 | 227 (130–360) | NA | 2.8 (1–5) | NA | 8.6 (5–17) | <300 | 0% | 0 | NA | NA | NA |
| Laparotomy | |||||||||||||
| Park et al. [ | 33 | NA | 275 ± 63 | 13 (9–16) | 14.5 ± 5.6 | 33.9 ±14.5 | 8.8 ± 8.1 | 568 ± 451 | 7 (21.2%) | 9 (27.3%) | 23 (1–44) | 0 | 0 |
| Park et al. [ | 19 | NA | 290 ± 121 | 32 | 14.1 ± 4.2 | 19.3 ± 10.1 | 6.4 ± 3.9 | 505.3 ± 279.8 | 6 (31.6%) | 7 (36.8%) | 14 ( 5–61) | 0 | 0 |
| Ghezzi et al. [ | 19 | NA | 272 ± 81 | NA | 7 (4–14) | 25.1 ± 5.8 | 7 ± 4.5 | 400 (150–1,000) | 6 (31.6%) | 8 (42.1%) | 60 (32–108) | 4 | 0 |
| Chi et al. [ | 30 | NA | 276 ± 68 | NA | 5.8 ± 2.6 | L, 7.1 ± 4.3 | L, 4.8 ± 4.2 | 367 ± 208 | NA | 2 (7%) | NA | NA | NA |
| R, 7.6 ± 3.8 | R, 4.4 ± 2.8 | ||||||||||||
| Spirtos et al. [ | 17 | NA | 218 ± 73 | NA | 7.31 ± 9.3 | L, 8.2 ± 5.0 | L, 4.6 ± 2.6 | 352.8 ± 415.0 | 8 (47%) | NA | NA | NA | 0 |
| R, 9.14 ± 9.9 | R, 4.4 ± 2.7 | ||||||||||||
Delay between initial OR and staging, PLN pelvic lymph nodes, PALN para-aortic lymph nodes, EBL estimated blood loss, Compl complications, R Recurrence, M Mortality (depending on what authors describe NA not available, − range, ± standard deviation)